Skip to main content
Top
Published in: Pediatric Rheumatology 1/2017

Open Access 01-12-2017 | Research article

A survey of national and multi-national registries and cohort studies in juvenile idiopathic arthritis: challenges and opportunities

Authors: Timothy Beukelman, Janneke Anink, Lillemor Berntson, Ciaran Duffy, Justine A. Ellis, Mia Glerup, Jaime Guzman, Gerd Horneff, Lianne Kearsley-Fleet, Ariane Klein, Jens Klotsche, Bo Magnusson, Kirsten Minden, Jane E. Munro, Martina Niewerth, Ellen Nordal, Nicolino Ruperto, Maria Jose Santos, Laura E. Schanberg, Wendy Thomson, Lisette van Suijlekom-Smit, Nico Wulffraat, Kimme Hyrich

Published in: Pediatric Rheumatology | Issue 1/2017

Login to get access

Abstract

Background

To characterize the existing national and multi-national registries and cohort studies in juvenile idiopathic arthritis (JIA) and identify differences as well as areas of potential future collaboration.

Methods

We surveyed investigators from North America, Europe, and Australia about existing JIA cohort studies and registries. We excluded cross-sectional studies. We captured information about study design, duration, location, inclusion criteria, data elements and collection methods.

Results

We received survey results from 18 studies, including 11 national and 7 multi-national studies representing 37 countries in total. Study designs included inception cohorts, prevalent disease cohorts, and new treatment cohorts (several of which contribute to pharmacosurveillance activities). Despite numerous differences, the data elements collected across the studies was quite similar, with most studies collecting at least 5 of the 6 American College of Rheumatology core set variables and the data needed to calculate the 3-variable clinical juvenile disease activity score. Most studies were collecting medication initiation and discontinuation dates and were attempting to capture serious adverse events.

Conclusion

There is a wide-range of large, ongoing JIA registries and cohort studies around the world. Our survey results indicate significant potential for future collaborative work using data from different studies and both combined and comparative analyses.
Literature
1.
go back to reference Petty RE, Southwood TR, Manners P, Baum J, Glass DN, Goldenberg J, et al. International league of associations for rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol. 2004;31:390–2.PubMed Petty RE, Southwood TR, Manners P, Baum J, Glass DN, Goldenberg J, et al. International league of associations for rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol. 2004;31:390–2.PubMed
2.
go back to reference Thierry S, Fautrel B, Lemelle I, Guillemin F. Prevalence and incidence of juvenile idiopathic arthritis: a systematic review. Joint Bone Spine. 2014;81:112–7.CrossRefPubMed Thierry S, Fautrel B, Lemelle I, Guillemin F. Prevalence and incidence of juvenile idiopathic arthritis: a systematic review. Joint Bone Spine. 2014;81:112–7.CrossRefPubMed
3.
go back to reference Guzman J, Gomez-Ramirez O, Jurencak R, Shiff NJ, Berard RA, Duffy CM, et al. What matters most for patients, parents, and clinicians in the course of juvenile idiopathic arthritis? a qualitative study. J Rheumatol. 2014;41:2260–9.CrossRefPubMed Guzman J, Gomez-Ramirez O, Jurencak R, Shiff NJ, Berard RA, Duffy CM, et al. What matters most for patients, parents, and clinicians in the course of juvenile idiopathic arthritis? a qualitative study. J Rheumatol. 2014;41:2260–9.CrossRefPubMed
4.
go back to reference van Pelt P, Wulffraat NM. Transition of care in rheumatology: managing the rheumatic patient from childhood to adulthood. In: Harrison A, editor. Insights and perspectives in rheumatology: InTech. 2012. p. 255–74. van Pelt P, Wulffraat NM. Transition of care in rheumatology: managing the rheumatic patient from childhood to adulthood. In: Harrison A, editor. Insights and perspectives in rheumatology: InTech. 2012. p. 255–74.
5.
go back to reference Ellis JA, Ponsonby AL, Pezic A, Chavez RA, Allen RC, Akikusa JD, et al. CLARITY - ChiLdhood arthritis risk factor identification sTudY. Pediatr Rheumatol Online J. 2012;10:37.CrossRefPubMedPubMedCentral Ellis JA, Ponsonby AL, Pezic A, Chavez RA, Allen RC, Akikusa JD, et al. CLARITY - ChiLdhood arthritis risk factor identification sTudY. Pediatr Rheumatol Online J. 2012;10:37.CrossRefPubMedPubMedCentral
6.
go back to reference Consolaro A, Ruperto N, Filocamo G, Lanni S, Bracciolini G, Garrone M, et al. Seeking insights into the EPidemiology, treatment and outcome of childhood arthritis through a multinational collaborative effort: introduction of the EPOCA study. Pediatr Rheumatol Online J. 2012;10:39.CrossRefPubMedPubMedCentral Consolaro A, Ruperto N, Filocamo G, Lanni S, Bracciolini G, Garrone M, et al. Seeking insights into the EPidemiology, treatment and outcome of childhood arthritis through a multinational collaborative effort: introduction of the EPOCA study. Pediatr Rheumatol Online J. 2012;10:39.CrossRefPubMedPubMedCentral
7.
go back to reference McErlane F, Foster HE, Davies R, Lunt M, Watson KD, Symmons DP, et al. Biologic treatment response among adults with juvenile idiopathic arthritis: results from the British society for rheumatology biologics register. Rheumatology (Oxford). 2013;52:1905–13.CrossRef McErlane F, Foster HE, Davies R, Lunt M, Watson KD, Symmons DP, et al. Biologic treatment response among adults with juvenile idiopathic arthritis: results from the British society for rheumatology biologics register. Rheumatology (Oxford). 2013;52:1905–13.CrossRef
8.
go back to reference Minden K, Niewerth M, Zink A, Seipelt E, Foeldvari I, Girschick H, et al. Long-term outcome of patients with JIA treated with etanercept, results of the biologic register JuMBO. Rheumatology (Oxford). 2012;51:1407–15.CrossRef Minden K, Niewerth M, Zink A, Seipelt E, Foeldvari I, Girschick H, et al. Long-term outcome of patients with JIA treated with etanercept, results of the biologic register JuMBO. Rheumatology (Oxford). 2012;51:1407–15.CrossRef
9.
go back to reference Canhao H, Faustino A, Martins F, Fonseca JE. Rheumatic diseases Portuguese register board coordination PSoR. Reuma.pt - the rheumatic diseases Portuguese register. Acta Reumatol Port. 2011;36:45–56.PubMed Canhao H, Faustino A, Martins F, Fonseca JE. Rheumatic diseases Portuguese register board coordination PSoR. Reuma.pt - the rheumatic diseases Portuguese register. Acta Reumatol Port. 2011;36:45–56.PubMed
10.
go back to reference Horneff G, De Bock F, Foeldvari I, Girschick HJ, Michels H, Moebius D, et al. Safety and efficacy of combination of etanercept and methotrexate compared to treatment with etanercept only in patients with juvenile idiopathic arthritis (JIA): preliminary data from the German JIA registry. Ann Rheum Dis. 2009;68:519–25.CrossRefPubMed Horneff G, De Bock F, Foeldvari I, Girschick HJ, Michels H, Moebius D, et al. Safety and efficacy of combination of etanercept and methotrexate compared to treatment with etanercept only in patients with juvenile idiopathic arthritis (JIA): preliminary data from the German JIA registry. Ann Rheum Dis. 2009;68:519–25.CrossRefPubMed
11.
go back to reference Schmeling H, Minden K, Foeldvari I, Ganser G, Hospach T, Horneff G. Efficacy and safety of adalimumab as the first and second biologic agent in juvenile idiopathic arthritis: the German biologics JIA registry. Arthritis Rheumatol. 2014;66:2580–9.CrossRefPubMed Schmeling H, Minden K, Foeldvari I, Ganser G, Hospach T, Horneff G. Efficacy and safety of adalimumab as the first and second biologic agent in juvenile idiopathic arthritis: the German biologics JIA registry. Arthritis Rheumatol. 2014;66:2580–9.CrossRefPubMed
12.
go back to reference Davies R, Southwood TR, Kearsley-Fleet L, Lunt M, Hyrich KL, British Society for P, et al. Medically significant infections Are increased in patients with juvenile idiopathic arthritis treated with etanercept: results from the British society for paediatric and adolescent rheumatology etanercept cohort study. Arthritis Rheumatol. 2015;67:2487–94.CrossRefPubMedPubMedCentral Davies R, Southwood TR, Kearsley-Fleet L, Lunt M, Hyrich KL, British Society for P, et al. Medically significant infections Are increased in patients with juvenile idiopathic arthritis treated with etanercept: results from the British society for paediatric and adolescent rheumatology etanercept cohort study. Arthritis Rheumatol. 2015;67:2487–94.CrossRefPubMedPubMedCentral
13.
go back to reference Kearsley-Fleet L, Davies R, Baildam E, Beresford MW, Foster HE, Southwood TR, et al. Factors associated with choice of biologic among children with juvenile idiopathic arthritis: results from two UK paediatric biologic registers. Rheumatology (Oxford). 2016;55:1556–65.CrossRef Kearsley-Fleet L, Davies R, Baildam E, Beresford MW, Foster HE, Southwood TR, et al. Factors associated with choice of biologic among children with juvenile idiopathic arthritis: results from two UK paediatric biologic registers. Rheumatology (Oxford). 2016;55:1556–65.CrossRef
14.
go back to reference Beukelman T, Kimura Y, Ilowite NI, Mieszkalski K, Natter MD, Burrell G, et al. The new Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry: design, rationale, and characteristics of patients enrolled in the first 12 months. (in press). Beukelman T, Kimura Y, Ilowite NI, Mieszkalski K, Natter MD, Burrell G, et al. The new Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry: design, rationale, and characteristics of patients enrolled in the first 12 months. (in press).
15.
go back to reference Filocamo G, Consolaro A, Schiappapietra B, Dalpra S, Lattanzi B, Magni-Manzoni S, et al. A new approach to clinical care of juvenile idiopathic arthritis: the juvenile arthritis multidimensional assessment report. J Rheumatol. 2011;38:938–53.CrossRefPubMed Filocamo G, Consolaro A, Schiappapietra B, Dalpra S, Lattanzi B, Magni-Manzoni S, et al. A new approach to clinical care of juvenile idiopathic arthritis: the juvenile arthritis multidimensional assessment report. J Rheumatol. 2011;38:938–53.CrossRefPubMed
16.
go back to reference Giannini EH, Ruperto N, Ravelli A, Lovell DJ, Felson DT, Martini A. Preliminary definition of improvement in juvenile arthritis. Arthritis Rheum. 1997;40:1202–9.CrossRefPubMed Giannini EH, Ruperto N, Ravelli A, Lovell DJ, Felson DT, Martini A. Preliminary definition of improvement in juvenile arthritis. Arthritis Rheum. 1997;40:1202–9.CrossRefPubMed
17.
go back to reference Consolaro A, Ruperto N, Bazso A, Pistorio A, Magni-Manzoni S, Filocamo G, et al. Development and validation of a composite disease activity score for juvenile idiopathic arthritis. Arthritis Rheum. 2009;61:658–66.CrossRefPubMed Consolaro A, Ruperto N, Bazso A, Pistorio A, Magni-Manzoni S, Filocamo G, et al. Development and validation of a composite disease activity score for juvenile idiopathic arthritis. Arthritis Rheum. 2009;61:658–66.CrossRefPubMed
18.
go back to reference McErlane F, Beresford MW, Baildam EM, Chieng SE, Davidson JE, Foster HE, et al. Validity of a three-variable juvenile arthritis disease activity score in children with new-onset juvenile idiopathic arthritis. Ann Rheum Dis. 2013;72:1983–8.CrossRefPubMed McErlane F, Beresford MW, Baildam EM, Chieng SE, Davidson JE, Foster HE, et al. Validity of a three-variable juvenile arthritis disease activity score in children with new-onset juvenile idiopathic arthritis. Ann Rheum Dis. 2013;72:1983–8.CrossRefPubMed
19.
go back to reference Adib N, Hyrich K, Thornton J, Lunt M, Davidson J, Gardner-Medwin J, et al. Association between duration of symptoms and severity of disease at first presentation to paediatric rheumatology: results from the childhood arthritis prospective study. Rheumatology (Oxford). 2008;47:991–5.CrossRef Adib N, Hyrich K, Thornton J, Lunt M, Davidson J, Gardner-Medwin J, et al. Association between duration of symptoms and severity of disease at first presentation to paediatric rheumatology: results from the childhood arthritis prospective study. Rheumatology (Oxford). 2008;47:991–5.CrossRef
20.
go back to reference Packham JC, Hall MA. Long-term follow-up of 246 adults with juvenile idiopathic arthritis: functional outcome. Rheumatology (Oxford). 2002;41:1428–35.CrossRef Packham JC, Hall MA. Long-term follow-up of 246 adults with juvenile idiopathic arthritis: functional outcome. Rheumatology (Oxford). 2002;41:1428–35.CrossRef
21.
go back to reference Bruinooge LN, El Moussaoui R, Taal E, Dijkmans BA, Van Soesbergen RM. Outcome in adults with juvenile idiopathic arthritis. Comparison of the DUTCH-AIMS2 between JIA and RA. Scand J Rheumatol. 2003;32:89–94.CrossRefPubMed Bruinooge LN, El Moussaoui R, Taal E, Dijkmans BA, Van Soesbergen RM. Outcome in adults with juvenile idiopathic arthritis. Comparison of the DUTCH-AIMS2 between JIA and RA. Scand J Rheumatol. 2003;32:89–94.CrossRefPubMed
22.
go back to reference Foster HE, Marshall N, Myers A, Dunkley P, Griffiths ID. Outcome in adults with juvenile idiopathic arthritis: a quality of life study. Arthritis Rheum. 2003;48:767–75.CrossRefPubMed Foster HE, Marshall N, Myers A, Dunkley P, Griffiths ID. Outcome in adults with juvenile idiopathic arthritis: a quality of life study. Arthritis Rheum. 2003;48:767–75.CrossRefPubMed
23.
go back to reference Peterson LS, Mason T, Nelson AM, O’Fallon WM, Gabriel SE. Psychosocial outcomes and health status of adults who have had juvenile rheumatoid arthritis: a controlled, population-based study. Arthritis Rheum. 1997;40:2235–40.CrossRefPubMed Peterson LS, Mason T, Nelson AM, O’Fallon WM, Gabriel SE. Psychosocial outcomes and health status of adults who have had juvenile rheumatoid arthritis: a controlled, population-based study. Arthritis Rheum. 1997;40:2235–40.CrossRefPubMed
24.
go back to reference Nordal E, Zak M, Aalto K, Berntson L, Fasth A, Herlin T, et al. Ongoing disease activity and changing categories in a long-term nordic cohort study of juvenile idiopathic arthritis. Arthritis Rheum. 2011;63:2809–18.CrossRefPubMed Nordal E, Zak M, Aalto K, Berntson L, Fasth A, Herlin T, et al. Ongoing disease activity and changing categories in a long-term nordic cohort study of juvenile idiopathic arthritis. Arthritis Rheum. 2011;63:2809–18.CrossRefPubMed
25.
go back to reference Zak M, Pedersen FK. Juvenile chronic arthritis into adulthood: a long-term follow-up study. Rheumatology (Oxford). 2000;39:198–204.CrossRef Zak M, Pedersen FK. Juvenile chronic arthritis into adulthood: a long-term follow-up study. Rheumatology (Oxford). 2000;39:198–204.CrossRef
26.
go back to reference French AR, Mason T, Nelson AM, O’Fallon WM, Gabriel SE. Increased mortality in adults with a history of juvenile rheumatoid arthritis: a population-based study. Arthritis Rheum. 2001;44:523–7.CrossRefPubMed French AR, Mason T, Nelson AM, O’Fallon WM, Gabriel SE. Increased mortality in adults with a history of juvenile rheumatoid arthritis: a population-based study. Arthritis Rheum. 2001;44:523–7.CrossRefPubMed
27.
go back to reference Arkela-Kautiainen M, Haapasaari J, Kautiainen H, Leppanen L, Vilkkumaa I, Malkia E, et al. Functioning and preferences for improvement of health among patients with juvenile idiopathic arthritis in early adulthood using the WHO ICF model. J Rheumatol. 2006;33:1369–76.PubMed Arkela-Kautiainen M, Haapasaari J, Kautiainen H, Leppanen L, Vilkkumaa I, Malkia E, et al. Functioning and preferences for improvement of health among patients with juvenile idiopathic arthritis in early adulthood using the WHO ICF model. J Rheumatol. 2006;33:1369–76.PubMed
28.
go back to reference Fantini F, Gerloni V, Gattinara M, Cimaz R, Arnoldi C, Lupi E. Remission in juvenile chronic arthritis: a cohort study of 683 consecutive cases with a mean 10 year followup. J Rheumatol. 2003;30:579–84.PubMed Fantini F, Gerloni V, Gattinara M, Cimaz R, Arnoldi C, Lupi E. Remission in juvenile chronic arthritis: a cohort study of 683 consecutive cases with a mean 10 year followup. J Rheumatol. 2003;30:579–84.PubMed
29.
go back to reference Selvaag AM, Aulie HA, Lilleby V, Flato B. Disease progression into adulthood and predictors of long-term active disease in juvenile idiopathic arthritis. Ann Rheum Dis. 2016;75:190–5.CrossRefPubMed Selvaag AM, Aulie HA, Lilleby V, Flato B. Disease progression into adulthood and predictors of long-term active disease in juvenile idiopathic arthritis. Ann Rheum Dis. 2016;75:190–5.CrossRefPubMed
30.
go back to reference Beukelman T, Xie F, Chen L, Baddley JW, Delzell E, Grijalva CG, et al. Rates of hospitalized bacterial infection associated with juvenile idiopathic arthritis and its treatment. Arthritis Rheum. 2012;64:2773–80.CrossRefPubMedPubMedCentral Beukelman T, Xie F, Chen L, Baddley JW, Delzell E, Grijalva CG, et al. Rates of hospitalized bacterial infection associated with juvenile idiopathic arthritis and its treatment. Arthritis Rheum. 2012;64:2773–80.CrossRefPubMedPubMedCentral
31.
go back to reference Beukelman T, Haynes K, Curtis JR, Xie F, Chen L, Bemrich-Stolz CJ, et al. Rates of malignancy associated with juvenile idiopathic arthritis and its treatment. Arthritis Rheum. 2012;64:1263–71.CrossRefPubMedPubMedCentral Beukelman T, Haynes K, Curtis JR, Xie F, Chen L, Bemrich-Stolz CJ, et al. Rates of malignancy associated with juvenile idiopathic arthritis and its treatment. Arthritis Rheum. 2012;64:1263–71.CrossRefPubMedPubMedCentral
32.
go back to reference Nordstrom BL, Mines D, Gu Y, Mercaldi C, Aquino P, Harrison MJ. Risk of malignancy in children with juvenile idiopathic arthritis not treated with biologic agents. Arthritis Care Res (Hoboken). 2012;64:1357–64.CrossRef Nordstrom BL, Mines D, Gu Y, Mercaldi C, Aquino P, Harrison MJ. Risk of malignancy in children with juvenile idiopathic arthritis not treated with biologic agents. Arthritis Care Res (Hoboken). 2012;64:1357–64.CrossRef
33.
go back to reference Robinson E, Albani S, Beresford MW, de Jager W, de Roock S, Duong T, et al. Towards stratified medicine in juvenile idiopathic arthritis [abstract]. 2016 Pediatric Rheumatology European Society (PReS) Congress. Robinson E, Albani S, Beresford MW, de Jager W, de Roock S, Duong T, et al. Towards stratified medicine in juvenile idiopathic arthritis [abstract]. 2016 Pediatric Rheumatology European Society (PReS) Congress.
34.
go back to reference Mercer LK, Askling J, Raaschou P, Dixon WG, Dreyer L, Hetland ML, et al. Risk of invasive melanoma in patients with rheumatoid arthritis treated with biologics: results from a collaborative project of 11 European biologic registers. Ann Rheum Dis. 2017;76(2):386–91. Mercer LK, Askling J, Raaschou P, Dixon WG, Dreyer L, Hetland ML, et al. Risk of invasive melanoma in patients with rheumatoid arthritis treated with biologics: results from a collaborative project of 11 European biologic registers. Ann Rheum Dis. 2017;76(2):386–91.
35.
go back to reference Sengler C, Klotsche J, Niewerth M, Liedmann I, Foll D, Heiligenhaus A, et al. The majority of newly diagnosed patients with juvenile idiopathic arthritis reach an inactive disease state within the first year of specialised care: data from a German inception cohort. RMD open. 2015;1:e000074.CrossRefPubMedPubMedCentral Sengler C, Klotsche J, Niewerth M, Liedmann I, Foll D, Heiligenhaus A, et al. The majority of newly diagnosed patients with juvenile idiopathic arthritis reach an inactive disease state within the first year of specialised care: data from a German inception cohort. RMD open. 2015;1:e000074.CrossRefPubMedPubMedCentral
36.
go back to reference Oen K, Tucker L, Huber AM, Miettunen P, Scuccimarri R, Campillo S, et al. Predictors of early inactive disease in a juvenile idiopathic arthritis cohort: results of a Canadian multicenter, prospective inception cohort study. Arthritis Rheum. 2009;61:1077–86.CrossRefPubMed Oen K, Tucker L, Huber AM, Miettunen P, Scuccimarri R, Campillo S, et al. Predictors of early inactive disease in a juvenile idiopathic arthritis cohort: results of a Canadian multicenter, prospective inception cohort study. Arthritis Rheum. 2009;61:1077–86.CrossRefPubMed
37.
go back to reference Beukelman T, Ringold S, Davis TE, DeWitt EM, Pelajo CF, Weiss PF, et al. Disease-modifying antirheumatic drug use in the treatment of juvenile idiopathic arthritis: a cross-sectional analysis of the CARRA Registry. J Rheumatol. 2012;39:1867–74.CrossRefPubMedPubMedCentral Beukelman T, Ringold S, Davis TE, DeWitt EM, Pelajo CF, Weiss PF, et al. Disease-modifying antirheumatic drug use in the treatment of juvenile idiopathic arthritis: a cross-sectional analysis of the CARRA Registry. J Rheumatol. 2012;39:1867–74.CrossRefPubMedPubMedCentral
38.
go back to reference Minden K, Niewerth M, Listing J, Zink A. German study group of pediatric R. Health care provision in pediatric rheumatology in Germany--national rheumatologic database. J Rheumatol. 2002;29:622–8.PubMed Minden K, Niewerth M, Listing J, Zink A. German study group of pediatric R. Health care provision in pediatric rheumatology in Germany--national rheumatologic database. J Rheumatol. 2002;29:622–8.PubMed
39.
go back to reference Prince FH, Twilt M, ten Cate R, van Rossum MA, Armbrust W, Hoppenreijs EP, et al. Long-term follow-up on effectiveness and safety of etanercept in juvenile idiopathic arthritis: the Dutch national register. Ann Rheum Dis. 2009;68:635–41.CrossRefPubMed Prince FH, Twilt M, ten Cate R, van Rossum MA, Armbrust W, Hoppenreijs EP, et al. Long-term follow-up on effectiveness and safety of etanercept in juvenile idiopathic arthritis: the Dutch national register. Ann Rheum Dis. 2009;68:635–41.CrossRefPubMed
Metadata
Title
A survey of national and multi-national registries and cohort studies in juvenile idiopathic arthritis: challenges and opportunities
Authors
Timothy Beukelman
Janneke Anink
Lillemor Berntson
Ciaran Duffy
Justine A. Ellis
Mia Glerup
Jaime Guzman
Gerd Horneff
Lianne Kearsley-Fleet
Ariane Klein
Jens Klotsche
Bo Magnusson
Kirsten Minden
Jane E. Munro
Martina Niewerth
Ellen Nordal
Nicolino Ruperto
Maria Jose Santos
Laura E. Schanberg
Wendy Thomson
Lisette van Suijlekom-Smit
Nico Wulffraat
Kimme Hyrich
Publication date
01-12-2017
Publisher
BioMed Central
Published in
Pediatric Rheumatology / Issue 1/2017
Electronic ISSN: 1546-0096
DOI
https://doi.org/10.1186/s12969-017-0161-5

Other articles of this Issue 1/2017

Pediatric Rheumatology 1/2017 Go to the issue